Overview

Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC

Status:
Recruiting
Trial end date:
2028-03-31
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the 1-year progression free survival (PFS) rate of tislelizumab combined with sitravatinib as assessed by investigators per RECIST 1.1.
Phase:
Phase 2
Details
Lead Sponsor:
Fudan University